Nektar Therapeutics Announces Start of Phase 3 ZENITH AD Program Evaluating Novel Regulatory T-Cell Biologic Rezpegaldesleukin in Moderate-to-Severe Atopic Dermatitis

Summary

Nektar Therapeutics has initiated two global Phase 3 registrational trials (ZENITH AD program) evaluating rezpegaldesleukin, a regulatory T-cell biologic, in moderate-to-severe atopic dermatitis, based on positive Phase 2b results from 393 patients showing clinically meaningful efficacy and favorable safety with monthly and quarterly dosing options.